New clues raise hopes for better treatment of RSV in babies. Future therapies for respiratory syncytial virus (RSV) must target both the virus and the immune response to ensure babies get the best possible outcomes, a new study by researchers at UCL and Great Ormond Street Hospital for Children (GOSH) finds.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Future therapies for respiratory syncytial virus (RSV) must target both the virus and the immune response to ensure babies get the best possible outcomes, a new study by researchers at UCL and Great Ormond Street Hospital for Children (GOSH) finds.
- Ponto de atenção: clues.
- Ponto de atenção: raise.
- Ponto de atenção: hopes.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/714bb402-38e3-43bf-8898-7556dcd88307.jpeg)
:quality(85)/b2559bc4-a3f9-4524-8599-e1e7c27867ef.png)
